U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Indolent Non-Hodgkin Lymphoma

MedGen UID:
233550
•Concept ID:
C1334170
•
Neoplastic Process
Synonym: Indolent Non-Hodgkin's Lymphoma

Definition

A non-Hodgkin lymphoma with an indolent clinical course. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVIndolent Non-Hodgkin Lymphoma

Professional guidelines

PubMed

Real-world management of small lymphocytic lymphoma as chronic lymphocytic leukaemia versus an indolent non-Hodgkin lymphoma.
Puckrin R, Owen C, Stewart D, Peters A
Br J Haematol 2023 Jul;202(2):445-448. Epub 2023 May 25 doi: 10.1111/bjh.18879. PMID: 37231889
High-risk follicular lymphoma: Treatment options.
Kahl B
Hematol Oncol 2021 Jun;39 Suppl 1:94-99. doi: 10.1002/hon.2853. PMID: 34105813
Indolent non-Hodgkin lymphoma treatment in the new drugs era.
Juárez-Salcedo LM, Dalia S
Chin Clin Oncol 2020 Dec;9(6):81. Epub 2020 Feb 11 doi: 10.21037/cco.2020.01.01. PMID: 32075392

Recent clinical studies

Etiology

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA
Blood 2024 Feb 8;143(6):496-506. doi: 10.1182/blood.2023021243. PMID: 37879047Free PMC Article
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
Phillips T, Chan H, Tam CS, Tedeschi A, Johnston P, Oh SY, Opat S, Eom HS, Allewelt H, Stern JC, Tan Z, Novotny W, Huang J, Trotman J
Blood Adv 2022 Jun 14;6(11):3472-3479. doi: 10.1182/bloodadvances.2021006083. PMID: 35390135Free PMC Article
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS
Lancet Oncol 2022 Jan;23(1):91-103. Epub 2021 Dec 8 doi: 10.1016/S1470-2045(21)00591-X. PMID: 34895487
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators
J Clin Oncol 2019 May 10;37(14):1188-1199. Epub 2019 Mar 21 doi: 10.1200/JCO.19.00010. PMID: 30897038Free PMC Article
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM
J Clin Oncol 2019 Apr 20;37(12):984-991. Epub 2019 Feb 27 doi: 10.1200/JCO.18.00605. PMID: 30811293Free PMC Article

Diagnosis

Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.
Merryman R, Mehtap Ö, LaCasce A
Turk J Haematol 2024 May 30;41(2):69-82. Epub 2024 Apr 25 doi: 10.4274/tjh.galenos.2024.2024.0015. PMID: 38660754Free PMC Article
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Leslie LA
Curr Treat Options Oncol 2021 Oct 25;22(12):111. doi: 10.1007/s11864-021-00909-1. PMID: 34694508Free PMC Article
High-risk follicular lymphoma: Treatment options.
Kahl B
Hematol Oncol 2021 Jun;39 Suppl 1:94-99. doi: 10.1002/hon.2853. PMID: 34105813
Targeting indolent non-Hodgkin lymphoma.
Leslie LA, Skarbnik AP, Bejot C, Stives S, Feldman TA, Goy AH
Expert Rev Hematol 2017 Apr;10(4):299-313. Epub 2017 Mar 15 doi: 10.1080/17474086.2017.1303374. PMID: 28277849
Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment.
Goel A, Fan W, Patel AA, Devabhaktuni M, Grossbard ML
Clin Lymphoma Myeloma Leuk 2014 Aug;14(4):261-70. Epub 2014 Feb 3 doi: 10.1016/j.clml.2014.01.006. PMID: 24650975

Therapy

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA
Blood 2024 Feb 8;143(6):496-506. doi: 10.1182/blood.2023021243. PMID: 37879047Free PMC Article
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
Phillips T, Chan H, Tam CS, Tedeschi A, Johnston P, Oh SY, Opat S, Eom HS, Allewelt H, Stern JC, Tan Z, Novotny W, Huang J, Trotman J
Blood Adv 2022 Jun 14;6(11):3472-3479. doi: 10.1182/bloodadvances.2021006083. PMID: 35390135Free PMC Article
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS
Lancet Oncol 2022 Jan;23(1):91-103. Epub 2021 Dec 8 doi: 10.1016/S1470-2045(21)00591-X. PMID: 34895487
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators
J Clin Oncol 2019 May 10;37(14):1188-1199. Epub 2019 Mar 21 doi: 10.1200/JCO.19.00010. PMID: 30897038Free PMC Article
Duvelisib in indolent non-Hodgkin lymphoma.
Das M
Lancet Oncol 2019 Mar;20(3):e138. Epub 2019 Feb 21 doi: 10.1016/S1470-2045(19)30101-9. PMID: 30799261

Prognosis

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA
Blood 2024 Feb 8;143(6):496-506. doi: 10.1182/blood.2023021243. PMID: 37879047Free PMC Article
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.
Hoskin P, Popova B, Schofield O, Brammer C, Robinson M, Brunt AM, Madhavan K, Illidge T, Gallop-Evans E, Syndikus I, Clifton-Hadley L, Kirkwood AA
Lancet Oncol 2021 Mar;22(3):332-340. Epub 2021 Feb 1 doi: 10.1016/S1470-2045(20)30686-0. PMID: 33539729
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM
J Clin Oncol 2019 Apr 20;37(12):984-991. Epub 2019 Feb 27 doi: 10.1200/JCO.18.00605. PMID: 30811293Free PMC Article
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH
J Clin Oncol 2018 Aug 1;36(22):2259-2266. Epub 2018 Mar 27 doi: 10.1200/JCO.2017.76.3656. PMID: 29584548
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD
Lancet Oncol 2016 Aug;17(8):1081-1093. Epub 2016 Jun 23 doi: 10.1016/S1470-2045(16)30097-3. PMID: 27345636

Clinical prediction guides

Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.
Merryman R, Mehtap Ö, LaCasce A
Turk J Haematol 2024 May 30;41(2):69-82. Epub 2024 Apr 25 doi: 10.4274/tjh.galenos.2024.2024.0015. PMID: 38660754Free PMC Article
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS
Lancet Oncol 2022 Jan;23(1):91-103. Epub 2021 Dec 8 doi: 10.1016/S1470-2045(21)00591-X. PMID: 34895487
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Leslie LA
Curr Treat Options Oncol 2021 Oct 25;22(12):111. doi: 10.1007/s11864-021-00909-1. PMID: 34694508Free PMC Article
High-risk follicular lymphoma: Treatment options.
Kahl B
Hematol Oncol 2021 Jun;39 Suppl 1:94-99. doi: 10.1002/hon.2853. PMID: 34105813
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM
J Clin Oncol 2019 Apr 20;37(12):984-991. Epub 2019 Feb 27 doi: 10.1200/JCO.18.00605. PMID: 30811293Free PMC Article

Recent systematic reviews

Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis.
Banerjee T, Kim MS, Haslam A, Prasad V
JAMA Intern Med 2023 May 1;183(5):435-441. doi: 10.1001/jamainternmed.2023.0190. PMID: 36939665Free PMC Article
Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z, Zhou H, Xu J, Wang J, Niu T
Front Immunol 2022;13:1070660. Epub 2023 Jan 4 doi: 10.3389/fimmu.2022.1070660. PMID: 36685572Free PMC Article
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.
Gagelmann N, Passamonti F, Wolschke C, Massoud R, Niederwieser C, Adjallé R, Mora B, Ayuk F, Kröger N
Haematologica 2022 Aug 1;107(8):1840-1849. doi: 10.3324/haematol.2021.280163. PMID: 34911284Free PMC Article
Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis.
Yuan T, Zhang F, Yao QM, Liu YX, Zhu XJ, Wang X
PLoS One 2017;12(5):e0177950. Epub 2017 May 22 doi: 10.1371/journal.pone.0177950. PMID: 28531181Free PMC Article
A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board.
Kuruvilla J, Assouline S, Hodgson D, MacDonald D, Stewart D, Christofides A, Komolova M, Connors J
Clin Lymphoma Myeloma Leuk 2015 Feb;15(2):59-74. Epub 2014 Aug 2 doi: 10.1016/j.clml.2014.07.015. PMID: 25195028

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...